Latest Breaking News On - Liposome research department - Page 1 : comparemela.com

Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

/PRNewswire/ Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical.

Innocan Pharma Corporation: Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

Innocan Pharma Corporation: Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsyThe dog was frequently hospitalized to stop seizure clusters Following

Innocan Pharma Corporation: Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development

Herzliya, Israel and Calgary, Alberta (Newsfile Corp. - July 12, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it